NASDAQ:TECH • US09073M1045
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIO-TECHNE CORP (TECH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-06 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-06 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-05 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-05 | UBS | Maintains | Buy -> Buy |
| 2026-02-05 | Stifel | Maintains | Hold -> Hold |
| 2026-02-05 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-05 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-05 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-11-20 | Argus Research | Maintains | Buy -> Buy |
| 2025-11-06 | UBS | Maintains | Buy -> Buy |
| 2025-11-06 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-14 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-03 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-08-21 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-08-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-07-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-07-09 | TD Cowen | Initiate | Buy |
| 2025-06-05 | Benchmark | Reiterate | Buy -> Buy |
| 2025-05-30 | Wells Fargo | Initiate | Overweight |
| 2025-05-09 | UBS | Maintains | Buy -> Buy |
| 2025-05-08 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-05-08 | Benchmark | Maintains | Buy -> Buy |
| 2025-05-08 | Stifel | Maintains | Hold -> Hold |
| 2025-04-09 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.137B 2.81% | 1.159B 1.97% | 1.22B 5.23% | 1.25B 2.49% | 1.33B 6.40% | 1.46B 9.77% | 1.56B 6.85% | 1.749B 12.12% | 2.186B 24.99% | 2.403B 9.93% | |
| EBITDA YoY % growth | 400.8M 0.38% | 362.87M -9.46% | 375.265M 3.42% | 448.04M 19.39% | 486.9M 8.67% | 541.6M 11.23% | 574.26M 6.03% | 579.36M 0.89% | 880.67M 52.01% | 988.58M 12.25% | |
| EBIT YoY % growth | 293.6M -1.54% | 251.159M -14.46% | 265.362M 5.65% | 405.1M 52.66% | 443.11M 9.38% | 501.66M 13.21% | 581.3M 15.88% | 748.68M 28.79% | 843.44M 12.66% | 949.82M 12.61% | |
| Operating Margin | 25.83% | 21.67% | 21.76% | 32.41% | 33.32% | 34.36% | 37.26% | 42.81% | 38.58% | 39.53% | |
| EPS YoY % growth | 2.00 1.01% | 1.78 -10.78% | 1.93 8.43% | 2.02 4.80% | 2.22 9.82% | 2.56 15.40% | 2.81 9.62% | 2.92 3.81% | N/A | N/A |
All data in USD
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.55 -2.08% | 0.57 8.45% | 0.47 11.79% | 0.52 12.25% | 0.61 10.79% | 0.64 11.21% | 0.50 6.45% | 0.56 8.65% | 0.66 9.14% | 0.71 10.90% |
| Revenue Q2Q % growth | 323.43M 2.29% | 334.11M 5.41% | 305.18M 6.50% | 321.3M 8.59% | 345.86M 6.94% | 357.14M 6.89% | 322.32M 5.62% | 341.29M 6.22% | 366.14M 5.86% | 382.36M 7.06% |
| EBITDA Q2Q % growth | 120.15M -26.13% | 125.83M -33.11% | 105.47M 34.39% | 114.04M 2.30% | 132.85M 10.57% | 138.09M 9.74% | 109.03M 3.38% | 119.32M 4.63% | 138.16M 4.00% | 149.56M 8.31% |
| EBIT Q2Q % growth | 109.58M 37.22% | 111.63M 42.72% | 93.873M 73.39% | 103.38M 65.59% | 120.83M 10.27% | 127.05M 13.81% | 99.134M 5.60% | 109.06M 5.49% | 127.79M 5.76% | 139.18M 9.55% |
All data in USD
23 analysts have analysed TECH and the average price target is 76.73 USD. This implies a price increase of 30.98% is expected in the next year compared to the current price of 58.58.
BIO-TECHNE CORP (TECH) will report earnings on 2026-05-06, before the market open.
The consensus EPS estimate for the next earnings of BIO-TECHNE CORP (TECH) is 0.55 USD and the consensus revenue estimate is 323.43M USD.
The expected long term growth rate for BIO-TECHNE CORP (TECH) is 5.57%.